Toward this, first, we acquired a dataset that contains pre-treatment tumor RNA-seq samples from 8 patients with EGFR-mutant lung cancer treated with the tyrosine kinase inhibitor, Osimertinib30. This evidence concerns the gene EGFR and lung carcinoma.